BAKER BROS. ADVISORS LP
Institutional investor · Portfolio as of Q3 2020
Top Holdings120 positions
SEAGEN INC | 47.3M | $9.3B | 37.0% | — | — | 1 qtr | New 98 |
BEONE MEDICINES LTD | 13.3M | $3.8B | 15.2% | $149.70 | +91.34% | 7 qtrssince 2019-Q1 | Increased 70 |
INCYTE CORP | 32M | $2.9B | 11.5% | $86.02 | +4.32% | 7 qtrssince 2019-Q1 | Increased 62 |
ACADIA PHARMACEUTICALS INC | 41.9M | $1.7B | 6.9% | $27.58 | +49.58% | 7 qtrssince 2019-Q1 | Unchanged 0 |
ALEXION PHARMACEUTICALS INC | 8.8M | $1B | 4.0% | — | — | 7 qtrssince 2019-Q1 | Unchanged 0 |
KODIAK SCIENCES INC | 12.4M | $731.4M | 2.9% | $21.68 | +173.13% | 7 qtrssince 2019-Q1 | Increased 58 |
BIOMARIN PHARMACEUTICAL INC | 7.6M | $577.4M | 2.3% | $88.83 | -14.44% | 7 qtrssince 2019-Q1 | Unchanged 0 |
ASCENDIS PHARMA A/S | 3.5M | $546.3M | 2.2% | $119.16 | +27.77% | 7 qtrssince 2019-Q1 | Increased 56 |
Invitae Corp | 11.9M | $513.7M | 2.1% | — | — | 7 qtrssince 2019-Q1 | Unchanged 0 |
MYOKARDIA INC | 3M | $410.3M | 1.6% | — | — | 7 qtrssince 2019-Q1 | Decreased 0 |
PRELUDE THERAPEUTICS INC | 10.1M | $304.9M | 1.2% | $28.84 | 0.00% | 1 qtr | New 71 |
ARGENX SE | 1M | $267.7M | 1.1% | $124.84 | +110.29% | 7 qtrssince 2019-Q1 | Unchanged 0 |
MIRATI THERAPEUTICS INC | 1.4M | $234.1M | 0.9% | — | — | 7 qtrssince 2019-Q1 | Unchanged 0 |
IGM BIOSCIENCES INC | 3.1M | $232.1M | 0.9% | — | — | 5 qtrssince 2019-Q3 | Increased 43 |
EXACT SCIENCES CORP | 1.8M | $188.2M | 0.8% | $91.87 | — | 4 qtrssince 2019-Q4 | Unchanged 0 |
MADRIGAL PHARMACEUTICALS INC | 1.5M | $178M | 0.7% | $112.39 | +5.65% | 7 qtrssince 2019-Q1 | Increased 43 |
AMARIN CORP PLC | 32M | $134.8M | 0.5% | $415.20 | -80.54% | 7 qtrssince 2019-Q1 | Decreased 0 |
HERON THERAPEUTICS INC | 6M | $88.8M | 0.4% | $23.47 | -36.85% | 7 qtrssince 2019-Q1 | Decreased 0 |
FORMA THERAPEUTICS HOLDINGS | 1.8M | $88.3M | 0.4% | — | — | 2 qtrssince 2020-Q2 | Decreased 0 |
CERUS CORP | 13.7M | $85.8M | 0.3% | $5.89 | +6.31% | 7 qtrssince 2019-Q1 | Unchanged 0 |
BAKER BROS. ADVISORS LP manages $25B across 120 positions as of Q3 2020. Top holdings: SGEN (37.0%), ONC (15.2%), INCY (11.5%). Fund DNA: Concentrated Value. HoldingsIntel Score: 3/5.0.
Active quarter - 14 new positions, 8 exits, 16 increased. Top move: SGEN (NEW, conviction 98). Portfolio: $25.0B across 120 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR